CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION RADIOLABEL MASS BALANCE DMPK OVERVIEW XENOGRAFT MODELS ADME SUMMARY REPORT.

Size: px
Start display at page:

Download "CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION RADIOLABEL MASS BALANCE DMPK OVERVIEW XENOGRAFT MODELS ADME SUMMARY REPORT."

Transcription

1 CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION RADIOLABEL MASS BALANCE XENOGRAFT MODELS DMPK OVERVIEW ADME SUMMARY REPORT DMPK Overview QPS provides immediate access to a dedicated team of experienced scientists to help select, design and conduct the appropriate ADME studies for your specific compound and therapeutic target

2 Introduction to QPS DMPK Services: For many, especially virtual, small and mid-size, pharmaceutical firms, outsourcing ADME studies to an experienced CRO such as QPS is a practical alternative to building or expanding an internal DMPK department. Outsourcing to QPS has many compelling advantages that are primarily associated with expanded expertise and improved cost effectiveness. HUMAN MASS BALANCE METABOLITE PROFILING TK MODELING METABOLITE IDENTIFICATION ADME FETUS RNAI THERAPEUTICS TISSUE DISTRIBUTION

3 The primary reasons why you should choose QPS as your preferred CRO for all your ADME sourcing needs. Direct Peer-to-Peer Interactions You get immediate access to a team of senior scientists that have 15+ years of pharmaceutical and biotech drug discovery and development experience. We will work with you to conduct the appropriate ADME studies across a broad range of compound structures and therapeutic targets. From In Vitro DDI and Metabolism studies to Whole-Body Autoradiography of a pregnant rat to Heart Autoradiography to Microautoradiography Furthermore, the same group of scientists also has additional 10+ years of CRO experience. Given this combination, QPS has breadth and depth from the perspective of the client as well as the service provider. You will benefit from direct peer-to-peer interactions and management of scientific, technical, and operational interactions by a seasoned scientist that has previously led discovery or development teams. Fast Turnaround Historical data clearly demonstrate that the direction taken by drug discovery and development is substantially influenced by ADME results. Our scientific experience, integrated services, and application of state-of-the-art bioanalytical equipment provides fast turnaround that will help you quickly arrive at go/no-go decisions thereby reducing your total developmental costs. Customer Focus Most of our senior level technical managers used to be involved with either contracting or monitoring out-sourced studies, so we understand exactly what is needed to be in a contracting partnership. We run your discovery and development programs with the ultimate care and commitment that you would expect from QPS.

4 MS 4 MS 3 MS 2 MS 1 MS 1 MS 4 MS 3 MS 2 Cost Effective Our DMPK department focuses on core services within our specific areas of expertise, and we integrate the various study components to gain additional efficiencies. This translates to improved overall project and time management which in turn translates to high quality, cost effectiveness and effective capacity utilization. QPS Delaware and Taiwan are both AAALAC accredited facilities and are both part of governmental GLP inspection programs. All regulatory-filing studies are performed in compliance according to the latest FDA or ICH or OECD guidance documents. QPS offers a full range of DMPK services including: Pharmacokinetics Formulation All Routes of Administration Bioanalysis PK/TK Modeling PK/PD Modeling Xenograft Models Protein Binding Radiolabel Tissue Distribution (QWBA & Micro-Autoradiography) Mass Balance/Excretion/BDC Metabolite Profiling, ID & Radio-quantitation Consulting Program Development Consulting Mechanistic Studies ADME Summary for Regulatory Submission Drug Metabolism Metabolic Stability Species Comparison Reaction Phenotyping Metabolite Profiling and Structural Elucidation Models to Evaluate Low CL int DDI Enzyme Induction CYP450 Inhibition Concomitant Medication(s) DDI Drug Transporters Efflux transporters (P-gp and BCRP) SLC Transporters (Hepatic and Renal) Hepatic Uptake (Passive vs. Active) Research Tools Custom Liver Co-culture Assays Custom Microsome Preparations Human Cryo Neurons TM Human Neural Stem Cells Liver Biomatrix Custom Media Production Assay Specific Hepatic Media Stem Cell Lineage Media

5 Call to arrange for a tour at one of QPS worldwide DMPK locations today QPS Delaware 2 QPS Hepatic Biosciences 2 QPS Taiwan

6 Time is of the essence in drug development, so contact a member Company Values: Integrity - We make and keep promises and build trust through honesty, proactive communication and reliability - Quality - We bring the highest level of technical expertise and judgement to our work - Customer Focus - We tap our global resources to provide service that is fast, flexible and integrated - Commitment - We work hard to solve problems and deliver results - People - We treat people with dignity, respect and fairness, and embrace our differences - Culture - We are friendly and fun. We provide opportunities to grow, we value loyalty and teamwork, and we recognize and reward performance. of the QPS Business Development Team today and find out what QPS can do for you. HQ BD Office Lily Rosa (USA) info@qps.com QPS Hepatic Biosciences 6 Davis Drive, RTP, NC 27709, USA HEPABIO ( )

DMPK Overview. QPS is your Global Link to all your DMPK Sourcing Needs DMPK OVERVIEW CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION

DMPK Overview. QPS is your Global Link to all your DMPK Sourcing Needs DMPK OVERVIEW CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION RADIOLABEL MASS BALANCE XENOGRAFT MODELS DMPK OVERVIEW ADME SUMMARY REPORT DMPK Overview QPS is your Global Link to all your DMPK Sourcing Needs Introduction

More information

DMPK Overview. DMPK Overview. CYP i NDUCTi ON. P r OTeiN Bi NDi NG. CYP i NHi B i T i ON. r ADi OLABe L MASS BALANCe. X e NOGr AFT MODe LS

DMPK Overview. DMPK Overview. CYP i NDUCTi ON. P r OTeiN Bi NDi NG. CYP i NHi B i T i ON. r ADi OLABe L MASS BALANCe. X e NOGr AFT MODe LS CYP i NDUCTi ON Q w BA P r OTeiN Bi NDi NG CYP i NHi B i T i ON r ADi OLABe L MASS BALANCe X e NOGr AFT MODe LS DMPK Overview ADMe SUMMAr Y repor T DMPK Overview QPS has three major preclinical discovery

More information

A drug development crossroad lies ahead

A drug development crossroad lies ahead G L O B A L C B O C O S T E F F E C T I V E B I O A N A L Y T I C A L H I G H Q U A L I T Y E A R L Y S T A G E C L I N I C A L T R A N S L A T I O N A L M E D I C I N E H I G H L Y C O M P E T E N T A

More information

Eurofins ADME BIOANALYSES Your partner in drug development

Eurofins ADME BIOANALYSES Your partner in drug development Eurofins ADME BIOANALYSES Your partner in drug development Since 1987, you have placed your confidence in us. Our responsibility, to which my staff and I commit, is to consistently provide you with relevant

More information

Introduction to Drug Development in Commercializing Biomedical Technology

Introduction to Drug Development in Commercializing Biomedical Technology Introduction to Drug Development in Commercializing Biomedical Technology Kevin W. Hunt, Ph.D. Director of Biopharmaceutical Product Development Office of Technology Development and Head of Translational

More information

SPEED UP YOUR TIME TO MARKET

SPEED UP YOUR TIME TO MARKET SPEED UP YOUR TIME TO MARKET #Pre-clinical #Biologics #Small molecules Welcome to Accelera. As a Contract Research Organization (CRO) serving since more than 30 years pharmaceutical and biotechnology companies

More information

Optimisation de votre programme de développement

Optimisation de votre programme de développement Optimisation de votre programme de développement Cedric Lamy, PhD. Cedric.lamy@crl.com Charles River Overview 65-year history: Founded in 1946, publicly traded (NYSE:CRL) Investment in skilled staff: ~7,500

More information

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report

More information

The Aptuit Center for Drug Discovery & Development Verona, Italy

The Aptuit Center for Drug Discovery & Development Verona, Italy The Aptuit Center for Drug Discovery & Development Verona, Italy 2 The Aptuit Center for Drug Discovery & Development Verona, Italy Aptuit in Verona: uncommon expertise, exceptional results A knowledgeable

More information

The course is taught by a team of UNC faculty and industry scientists. The course has been designed to provide the students an understanding of

The course is taught by a team of UNC faculty and industry scientists. The course has been designed to provide the students an understanding of Drug Metabolism MOPH 810 Fall 2009 Classes: 80 minute class twice a week Course Director: Dhiren R. Thakker Eshelman School of Pharmacy, UNC-Chapel Hill The course is taught by a team of UNC faculty and

More information

Envigo Corporate & Industry Overview. Rutgers University

Envigo Corporate & Industry Overview. Rutgers University Envigo Corporate & Industry Overview Rutgers University Joseph Bedford, Ph.D. Corporate Vice President, Strategic Marketing November 15, 2016 envigo.com 1 Who we are Envigo is a global contract research

More information

PRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016

PRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016 PRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016 1 FROM DISCOVERY TO COMMERCIALIZATION At least 10 years on average Average spend of $1.4B Less than 12% of drugs entering Phase I are approved

More information

The TetraQ Difference. Quality Preclinical Drug Development Solutions. Provide advice and tailored solutions, not just a menu of choices

The TetraQ Difference. Quality Preclinical Drug Development Solutions. Provide advice and tailored solutions, not just a menu of choices A leading Australian contract research organisation (CRO) providing integrated preclinical drug development services to the biotech and pharmaceutical industries The TetraQ Difference Located at The University

More information

A full-service CRO with integrated early-stage capabilities

A full-service CRO with integrated early-stage capabilities CHARLES RIVER TO ACQUIRE ARGENTA and BIOFOCUS A full-service CRO with integrated early-stage capabilities James C. Foster Chairman, President & CEO Thomas F. Ackerman Executive Vice President & CFO March

More information

vitro Toxicology Analysis

vitro Toxicology Analysis Anthony D Baxter, CEO New High Content Screening Methods Applied to in vitro Toxicology Analysis Better decisions. Earlier in the game. Enquiries@cyprotex.com Business overview A uniquely packaged ADMET

More information

The Right Molecules. Designed. Delivered.

The Right Molecules. Designed. Delivered. The Right Molecules. Designed. Delivered. 400+ Worldwide Clients 80+ Medicinal Chemistry Programs 20+ Preclinical Candidates Delivered Since 2008 10+ In IND Stage 5 Entered Phase I Clinical Trials 2 Entered

More information

drug discovery: Where are we now? How did we RSC February 2013

drug discovery: Where are we now? How did we RSC February 2013 The role of pharmacokinetics in drug discovery: Where are we now? How did we get th here??where are we going? Peter Webborn RSC February 2013 Why conduct PK studies in animals? The primary purpose of pre-clinical

More information

Celerion s Symposia Series: Bridging the Gap from Phase I to Proof-of-Concept. San Francisco, CA Tue 8 th, Apr 2014

Celerion s Symposia Series: Bridging the Gap from Phase I to Proof-of-Concept. San Francisco, CA Tue 8 th, Apr 2014 Celerion s Symposia Series: Bridging the Gap from Phase I to Proof-of-Concept San Francisco, CA Tue 8 th, Apr 2014 Mind the Gap: Elements of a Bridging Strategy J. Fred Pritchard, Ph.D. Vice President,

More information

PAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey

PAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey PAREXEL GENOMIC MEDICINE SERVICES Applying genomics to enhance your drug development journey YOUR JOURNEY. OUR MISSION. Genomic expertise to simplify the route to product approval and maximize patient

More information

Preclinical Drug Development

Preclinical Drug Development Preclinical Drug Development A guidance prepared by From a 2004 NIH Summit Workshop: A major reason for the tremendous cost of drug development is the high rate of drug candidate failure during clinical

More information

Pharmaceutical LC/MS Solutions from Agilent Technologies

Pharmaceutical LC/MS Solutions from Agilent Technologies Pharmaceutical LC/MS Solutions from Agilent Technologies Application Compendium Overview LC/MS plays a key role in the drug discovery and drug development process. Since the introduction of electrospray

More information

Science. Enhancing the Pharma-CRO relationship with a focus on method transfer. for a safer world

Science. Enhancing the Pharma-CRO relationship with a focus on method transfer. for a safer world Enhancing the Pharma-CRO relationship with a focus on method transfer Chris Jones, Client Manager, Drug Development Services, LGC EBF Open Symposium, 18 th November 2015 Science for a safer world Overview

More information

Informatics and High Resolution QTof MS. How can we ask better questions and get better answers in DMPK? Mark D. Wrona

Informatics and High Resolution QTof MS. How can we ask better questions and get better answers in DMPK? Mark D. Wrona Informatics and High Resolution QTof MS How can we ask better questions and get better answers in DMPK? Mark D. Wrona Principal Scientist Pharmaceutical & Life Sciences, Waters Corporation Pacific Northwest

More information

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from

More information

Outsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing

Outsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing Outsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing By Impact Analytical Introduction About Impact Analytical Impact Analytical is a contract analytical testing

More information

The Role of a Clinical Statistician in Drug Development By: Jackie Reisner

The Role of a Clinical Statistician in Drug Development By: Jackie Reisner The Role of a Clinical Statistician in Drug Development By: Jackie Reisner Types of studies within clinical development Phase I Phase II Phase III Phase IV Phase I First Human Dose (FHD) Young healthy

More information

Dr Amy Prosser Careers in Research: Industry

Dr Amy Prosser Careers in Research: Industry www.rsb.org.uk Dr Amy Prosser Careers in Research: Industry @RoyalSocBio #BiologyWeek #RSBcareersDay Careers in Research: Working in the Pharma Industry Dr Amy Prosser My Career History 2011 Completed

More information

European Medicines Agency Evaluation of Medicines for Human Use COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT

European Medicines Agency Evaluation of Medicines for Human Use COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT European Medicines Agency Evaluation of Medicines for Human Use London, 27 July 2005 EMEA/CHMP/89249/2004 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT Guideline on the Clinical Investigation

More information

BIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program

BIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program BIOPHARMA SOLUTIONS TM Expedite Your Drug Program Maximize the Value of Your Asset The journey of drug development can be complex stressful. But it doesn t have to be that way. Join more than 600 biopharmaceutical

More information

Agilent RapidFire 360 High-throughput Mass Spectrometry System. Innovative Integrated Technology

Agilent RapidFire 360 High-throughput Mass Spectrometry System. Innovative Integrated Technology Agilent RapidFire 360 High-throughput Mass Spectrometry System Innovative Integrated Technology Agilent RapidFire High-throughput Mass Spectrometry system Streamline workflows and eliminate bottlenecks

More information

MDI Manufacturing Services

MDI Manufacturing Services MDI Manufacturing Services Presenter, Date Who we are 3M Drug Delivery Systems is a division of 3M dedicated to working together with pharmaceutical and biotech companies to bring new and improved products

More information

Introduction of Development Center for Biotechnology TAIWAN

Introduction of Development Center for Biotechnology TAIWAN Introduction of Development Center for Biotechnology TAIWAN DCB Nonprofit Organization Founded in 1984 Funded Mainly by Ministry of Economic Affairs (MOEA), National Science Council and the Industry 394

More information

Early Phase Education WHITEPAPER. Three major items to consider when moving from preclinical to clinical development

Early Phase Education WHITEPAPER. Three major items to consider when moving from preclinical to clinical development Early Phase Education WHITEPAPER Three major items to consider when moving from preclinical to clinical development Three major items to consider when moving from preclinical to clinical development Dr.

More information

Novel Cytochrome P450 Reaction Phenotyping for Low-Clearance Compounds Using the Hepatocyte Relay Method. Li Di, Ph.D. Pfizer Inc.

Novel Cytochrome P450 Reaction Phenotyping for Low-Clearance Compounds Using the Hepatocyte Relay Method. Li Di, Ph.D. Pfizer Inc. Novel Cytochrome P450 Reaction Phenotyping for Low-Clearance Compounds Using the Hepatocyte Relay Method Li Di, Ph.D. Pfizer Inc. June 21, 2017 Challenges of Low Clearance Low clearance goal of drug discovery

More information

Pharmaceutical Sciences

Pharmaceutical Sciences SRI International Biosciences From Idea to IND Research on Disease Mechanisms Drug Discovery Drug Metabolism, Pharmacokinetics, & Toxicology Services Pharmaceutical Sciences Preclinical Development Planning

More information

High Throughput CYP Inhibition Assays Using RapidFire Mass Spectrometry and Conventional Drug Probe Substrates

High Throughput CYP Inhibition Assays Using RapidFire Mass Spectrometry and Conventional Drug Probe Substrates High Throughput CYP Inhibition Assays Using RapidFire Mass Spectrometry and Conventional Drug Probe Substrates David M. Stresser, Ph.D. Program Manager BD Gentest SM Contract Research Services Presentation

More information

PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials. Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis

PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials. Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis Disclaimer Contents are the opinion of the author and not that of Novartis

More information

A Global CRO STRONGER TOGETHER

A Global CRO STRONGER TOGETHER A Global CRO STRONGER TOGETHER About us Unique Service Offering the first agrochemical CRO to offer a truly global service Part of the Eurofins Scientific Group of companies, Eurofins Agroscience Services

More information

Simultaneous in vivo Quantification and Metabolite Identification of Plasma Samples Using High Resolution QTof and Routine MS E Data Analysis

Simultaneous in vivo Quantification and Metabolite Identification of Plasma Samples Using High Resolution QTof and Routine MS E Data Analysis Simultaneous in vivo Quantification and Metabolite Identification of Plasma Samples Using High Resolution QTof and Routine MS E Data Analysis Mark Wrona, 1 Paul Rainville, 1 Eric Langlois, 2 Nigel Ewing,

More information

SKIN BIOLOGY A VALUABLE TOOL FOR THE INNOVATION AND DEVELOPMENT OF NOVEL THERAPEUTIC ALTERNATIVES IN DERMATOLOGY

SKIN BIOLOGY A VALUABLE TOOL FOR THE INNOVATION AND DEVELOPMENT OF NOVEL THERAPEUTIC ALTERNATIVES IN DERMATOLOGY SKIN BIOLOGY A VALUABLE TOOL FOR THE INNOVATION AND DEVELOPMENT OF NOVEL THERAPEUTIC ALTERNATIVES IN DERMATOLOGY COMPANY BACKGROUND Specializes in liquid and semi-solid topical products Rx, OTC & Therapeutic

More information

Inaugural Fraunhofer Delaware Technology Summit

Inaugural Fraunhofer Delaware Technology Summit Inaugural Fraunhofer Delaware Technology Summit Energy and Life Sciences Solu

More information

Use of Antisense Oligonucleotides for the Treatment of Inheritable Rare Disorders. C. Frank Bennett Isis Pharmaceuticals

Use of Antisense Oligonucleotides for the Treatment of Inheritable Rare Disorders. C. Frank Bennett Isis Pharmaceuticals Use of Antisense ligonucleotides for the Treatment of Inheritable Rare Disorders C. Frank Bennett Isis Pharmaceuticals Agenda Review different antisense strategies Delivery of oligonucleotides to the skin,

More information

Bench-to-Bedside Translation of ADCs using PK/PD M&S. Dhaval K. Shah, Ph.D.

Bench-to-Bedside Translation of ADCs using PK/PD M&S. Dhaval K. Shah, Ph.D. Bench-to-Bedside Translation of ADCs using PK/PD M&S Dhaval K. Shah, Ph.D. dshah4@buffalo.edu 8/23/2016 Outline Overview: ADCs Prediction of Clinical Efficacy using a Multi-Scale Mechanistic PK/PD Model

More information

Global Development Challenges: Classical and Advanced Therapy Medicinal products

Global Development Challenges: Classical and Advanced Therapy Medicinal products Global Development Challenges: Classical and Advanced Therapy Medicinal products Beatriz Silva Lima imed, Lisbon University and Infarmed,, Portugal CHMP, CAT, SAWP Member and SWP Chair NONCLINICAL STUDIES

More information

TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT

TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise

More information

The views and opinions expressed in the following PowerPoint slides are

The views and opinions expressed in the following PowerPoint slides are Indications, Dosage and Administration, Clinical Studies, Clinical Pharmacology sections of a CCDS Presented by: Mary Jane Boyle Head, Worldwide Product Labeling Merck & Co., 13-October-2011 The views

More information

PHARMACEUTICAL BIOANALYSIS BIOANALYSIS SERVICES. Bioanalytical Expertise for Large and Small Molecules

PHARMACEUTICAL BIOANALYSIS BIOANALYSIS SERVICES. Bioanalytical Expertise for Large and Small Molecules PHARMACEUTICAL BIOANALYSIS BIOANALYSIS SERVICES Bioanalytical Expertise for Large and Small Molecules Our Bioanalytical Expertise Bioanalysis plays a critical role in the assessment of drug safety and

More information

Samatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus (HCV) Infection

Samatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus (HCV) Infection Samatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus (HCV) Infection Douglas Mayers, MD December 11, 2013 1 Idenix: Advancing All-Oral, Pan-Genotypic Combination

More information

Preclinical pharmacokinetics and pharmacodynamics of AG-519, an allosteric pyruvate kinase activator

Preclinical pharmacokinetics and pharmacodynamics of AG-519, an allosteric pyruvate kinase activator S830 Preclinical pharmacokinetics and pharmacodynamics of AG-519, an allosteric pyruvate kinase activator Yue Chen, Raj Nagaraja, Kha Le, Penelope A Kosinski, Gavin Histen, Charles Kung, Hyeryun Kim, Chandra

More information

Value Scale (1-5) 1 I. Final Product Profile Characteristics of the product required for patient care

Value Scale (1-5) 1 I. Final Product Profile Characteristics of the product required for patient care In this example, the majority of the compounds was active in the xenograft model and showed "drug-like" properties from in-silico and experimental data. However, the animal studies showed moderate toxicity

More information

DRUG CANDIDATE ASSESSMENT PACKAGE

DRUG CANDIDATE ASSESSMENT PACKAGE DRUG CANDIDATE ASSESSMENT PACKAGE Eurofins Cerep Panlabs has developed this package in response to many questions from our clients about the type of data that is useful in moving their drug candidates

More information

4th ANTWERP BIOPHARM DAY SAFETY & EFFICACY CLINICAL TRIALS SOLUTIONS DATE: OCTOBER 29, 2015

4th ANTWERP BIOPHARM DAY SAFETY & EFFICACY CLINICAL TRIALS SOLUTIONS DATE: OCTOBER 29, 2015 4th ANTWERP BIOPHARM DAY SAFETY & EFFICACY CLINICAL TRIALS SOLUTIONS DATE: OCTOBER 29, 2015 VENUE: LINDNER HOTEL LANGE KIEVITSTRAAT 125 BE-2018 ANTWERP, BELGIUM 2 Join the 4 th one-day seminar to discuss

More information

Silensomes CYP Phenotyping Kit Technical Information & Instructions

Silensomes CYP Phenotyping Kit Technical Information & Instructions Lonza Walkersville, Inc. Walkersville, MD 21793-0127 USA U.S. Scientific Support: 800 521 0390 scientific.support@lonza.com EU/ROW Scientific Support: +32 87 321 611 scientific.support.eu@lonza.com Document

More information

Translational Modeling

Translational Modeling sbv Improver Symposium October 30, 2013 Athens, Greece Translational Modeling Impact on Critical Decision Making in Drug Development Carolyn Cho, M&S, MSD. Views expressed are of the speaker and do not

More information

Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017

Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017 Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts (2017-2021) November 2017 Global Contract Research Organization (CRO) Market : Coverage Executive Summary and Scope Introduction/Market

More information

PHARMACEUTICAL TESTING

PHARMACEUTICAL TESTING WHITEHOUSE, NJ PHARMACEUTICAL TESTING Pharmaceutical Expertise for GMP & CMC Testing Our Pharmaceutical Expertise With more than 20 years of experience in a variety of industries, our Whitehouse, New Jersey

More information

Adding value to Indigenous Knowledge through Scientific Innovation

Adding value to Indigenous Knowledge through Scientific Innovation THE WORLD BANK Adding value to Indigenous Knowledge through Scientific Innovation INTERNATIONAL WORKSHOP ON INDIGENOUS KNOWLEDGE Benoni, South Africa 9-11 February 2005 Marthinus Horak Programme CSIR Bio/Chemtek

More information

Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation

Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation 1 2 3 21 July 2016 EMA/CHMP/458101/2016 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling

More information

SHORT COURSE. Practical Considerations for Biomarker Bioanalysis: Scientific and Regulatory Perspective SUNDAY, SEPTEMBER 17

SHORT COURSE. Practical Considerations for Biomarker Bioanalysis: Scientific and Regulatory Perspective SUNDAY, SEPTEMBER 17 SHORT COURSE SUNDAY, SEPTEMBER 17 OMNI PROVIDENCE HOTEL PROVIDENCE, RI Practical Considerations for Biomarker Bioanalysis: Scientific and Regulatory Perspective SPONSORED BY: Organized by: www.bostonsociety.org

More information

The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to

The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to advance candidates from development through commercialization

More information

Novartis Business Services HR University Relations. Clinical Sciences and Innovation. Postgraduate Program

Novartis Business Services HR University Relations. Clinical Sciences and Innovation. Postgraduate Program Novartis Business Services HR University Relations Clinical Sciences and Innovation Postgraduate Program 2 CLINICAL SCIENCES AND INNOVATION CLINICAL SCIENCES AND INNOVATION 3 The CS&I Postgraduate Program

More information

THE INNOVATION COMPANY HEALTH. Institute for Biomedicine and Health Sciences

THE INNOVATION COMPANY HEALTH. Institute for Biomedicine and Health Sciences THE INNOVATION COMPANY HEALTH Institute for Biomedicine and Health Sciences Our central activity is innovative applied research that bridges the gap between basic research and industrial applications.

More information

The Long Range Science Strategy (LRSS) of Cosmetics Europe

The Long Range Science Strategy (LRSS) of Cosmetics Europe The Long Range Science Strategy (LRSS) of Cosmetics Europe Repeated dose systemic toxicity 2016 Bas Blaauboer Aim of LRSS: Development of a strategy to determine safety of cosmetic ingredients and products

More information

WuXi PharmaTech: Building an Open-Access Capability and Technology Platform. Jefferies Healthcare Conference November 2014

WuXi PharmaTech: Building an Open-Access Capability and Technology Platform. Jefferies Healthcare Conference November 2014 WuXi PharmaTech: Building an Open-Access Capability and Technology Platform Jefferies Healthcare Conference November 2014 Cautionary Note Regarding Forward-Looking Statements This presentation contains

More information

Adopting Virtual R&D in Drug Development

Adopting Virtual R&D in Drug Development Adopting Virtual R&D in Drug Development 2016 Table of Contents 1. Why virtual R&D? 2. Project management team for drug development 3. Project initiation 4. Clinical study team considerations for virtual

More information

The room was more than 3/4 full with greater than 150 people in attendance.

The room was more than 3/4 full with greater than 150 people in attendance. Summary The room was more than 3/4 full with greater than 150 people in attendance. The questions were well distributed across all four panelists. All the Panelists were very interactive and were able

More information

CRO partner in Rx/CDx Co-Development

CRO partner in Rx/CDx Co-Development CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics

More information

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities

More information

Pharmacology. Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University.

Pharmacology. Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University. Pharmacology Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University. 1 PHARMACODYNAMIC STUDIES A. Primary pharmacodynamics primary action in target

More information

Synthesis to Clinic 14 C studies in man a Chemistry. Stephen Lewinton Managing Director Chemistry & Metabolism Feb 2013

Synthesis to Clinic 14 C studies in man a Chemistry. Stephen Lewinton Managing Director Chemistry & Metabolism Feb 2013 Synthesis to Clinic 14 C studies in man a Chemistry perspective Stephen Lewinton Managing Director Chemistry & Metabolism Feb 2013 Synthesis-to-Clinic 14 C API synthesis Preclinical Data Regulatory affairs

More information

In vitro mechanistic studies on Metabolism-Dependent Inactivation of Cytochrome P450 Enzymes

In vitro mechanistic studies on Metabolism-Dependent Inactivation of Cytochrome P450 Enzymes In vitro mechanistic studies on Metabolism-Dependent Inactivation of Cytochrome P450 Enzymes Brooke Rock, 2016 DDI Conference, Seattle, WA Acknowledgements: PKDM, Amgen, San rancisco Chi-Chi Peng, John

More information

ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions. Step 3

ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions. Step 3 European Medicines Agency June 2009 EMEA/CHMP/ICH/380636/2009 ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions Step 3 NOTE FOR GUIDANCE

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS European Medicines Agency London, 24 January 2008 Doc. Ref. EMEA/CHMP/SWP/258498/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS

More information

Increased Sensitivity through GC- MS/MS

Increased Sensitivity through GC- MS/MS Introducing InVentiv Health Clinical Important Impact of GLP Certification Dr. Jim Settlage joins our team Success Story & Client Testimonial New Technology for Improved Quantitation and Sensitivity Increased

More information

Reflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug development

Reflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug development 1 2 3 24 June 2010 EMA/CHMP/641298/2008 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Reflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug

More information

Team A2 : Tiered Approaches to Method Validation

Team A2 : Tiered Approaches to Method Validation Team A2 : Tiered Approaches to Method Validation Why are Tiered Approaches Deemed Necessary? Bioanalysis has evolved into Bioequivalence Bioanalysis : v In the interest of avoiding any regulatory critique

More information

"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia

From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia "From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia Damir Hamamdžić D.V.M., Ph.D. Office of Research Regulatory Affairs Rutgers University RWJMS

More information

Paracelsus Course Objectives: Toxicology for the Laboratory Animal Scientist. General Toxicology Investigations. Reproductive Toxicology

Paracelsus Course Objectives: Toxicology for the Laboratory Animal Scientist. General Toxicology Investigations. Reproductive Toxicology Toxicology for the Laboratory Animal Scientist CL Davis Foundation Topics in Laboratory Animal Medicine May 7, 2009 Angela King-Herbert, DVM, DACLAM NTP/NIEHS RTP NC Course Objectives: Define terms used

More information

S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers

S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers Current version dated 8 June 2016 International Council for Harmonisation of

More information

RE: CPMT Pharmacokinetic Analyses of Fixed-Dose Drug Combinations for Pediatric Tuberculosis

RE: CPMT Pharmacokinetic Analyses of Fixed-Dose Drug Combinations for Pediatric Tuberculosis Suzanne Hill, M.D. Essential Medicines and Pharmaceutical Policies World Health Organization Geneva, Switzerland RE: CPMT-08-011 Pharmacokinetic Analyses of Fixed-Dose Drug Combinations for Pediatric Tuberculosis

More information

Bioengineering to reduce animal use and improve drug development

Bioengineering to reduce animal use and improve drug development Bioengineering to reduce animal use and improve drug development Anthony Holmes PhD Programme Manager Technology Development NC3Rs Institute of Bioengineering Launch Event Queen Mary, University of London

More information

MAYO CLINIC CENTER FOR BIOMEDICAL DISCOVERY EXCEPTIONAL RESEARCH LEADS TO EXCEPTIONAL PATIENT CARE

MAYO CLINIC CENTER FOR BIOMEDICAL DISCOVERY EXCEPTIONAL RESEARCH LEADS TO EXCEPTIONAL PATIENT CARE MAYO CLINIC CENTER FOR BIOMEDICAL DISCOVERY EXCEPTIONAL RESEARCH LEADS TO EXCEPTIONAL PATIENT CARE THE RESEARCH WE DO TODAY WILL DETERMINE THE TYPE OF MEDICAL AND SURGICAL PRACTICE WE CARRY ON AT THE CLINIC

More information

Analytical Methods Development and Validation

Analytical Methods Development and Validation Understanding and Implementing Efficient Analytical Methods Development and Validation Jay Breaux, Kevin Jones, and Pierre Boulas Analytical methods development and validation play important roles in the

More information

Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development

Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration

More information

Drug-Device Combination Product Development: INDs for Device Companies

Drug-Device Combination Product Development: INDs for Device Companies Drug-Device Combination Product Development: INDs for Device Companies David Armbruster Global Program Manager April 24, 2013 Drug-Device Combination Product Development -or- The scenic route to an IND

More information

Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies

Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies The value of In Vitro Diagnostics The value of diagnostics as an integral part in the healthcare value chain Diagnostics

More information

Technology Development Funding Program Round 3

Technology Development Funding Program Round 3 Technology Development Funding Program Round 3 CWRU January 26, 2015 1 Program Overview NIH Center for Accelerated Innovations (NCAI) at Cleveland Clinic Mission to improve translation of basic science

More information

World-leading LC/MS/MS technology for quantitation and identification API LC/MS/MS System

World-leading LC/MS/MS technology for quantitation and identification API LC/MS/MS System World-leading LC/MS/MS technology for quantitation and identification API 3000 LC/MS/MS System rel Accelerate your drug development cycle The API 3000 LC/MS/MS System leads the field in sensitivity, specificity,

More information

FCT PhD Programme Medicines and Pharmaceutical Innovation (i3du)

FCT PhD Programme Medicines and Pharmaceutical Innovation (i3du) FCT PhD Programme Medicines and Pharmaceutical Innovation (i3du) Course BIOMARKERS AND ASSAY DEVELOPMENT February 6-10, 2017 Faculty of Pharmacy Amphitheatre B Universidade de Lisboa, Portugal The FCT

More information

DISCOVERY AND VALIDATION OF TARGETS AND BIOMARKERS BY MASS SPECTROMETRY-BASED PROTEOMICS. September, 2011

DISCOVERY AND VALIDATION OF TARGETS AND BIOMARKERS BY MASS SPECTROMETRY-BASED PROTEOMICS. September, 2011 DISCOVERY AND VALIDATION OF TARGETS AND BIOMARKERS BY MASS SPECTROMETRY-BASED PROTEOMICS September, 2011 1 CAPRION PROTEOMICS Leading proteomics-based service provider - Biomarker and target discovery

More information

INTRODUCTION PATRICK POULIN, 1,2 SAMI HADDAD 2

INTRODUCTION PATRICK POULIN, 1,2 SAMI HADDAD 2 RESEARCH ARTICLE Pharmacokinetics, Pharmacodynamics and Drug Transport and Metabolism Albumin and Uptake of Drugs in Cells: Additional Validation Exercises of a Recently Published Equation that Quantifies

More information

Structure and content of an IMPD. What is required for first into man trial?

Structure and content of an IMPD. What is required for first into man trial? What is required for first into man? The EU IMPD Thomas Sudhop, MD Scope Structure and content of an IMPD What is required for first into man trial? Only for IMPs that do not have a marketing authorisation

More information

Establishment of Clinical Trial Infrastructure

Establishment of Clinical Trial Infrastructure Taiwan s Strategy in the Establishment of Clinical Trial Infrastructure Chei-Hsiang Chen, Ph. D. Director, Biotechnology and Pharmaceutical Industries Program Office, Ministry of Economic Affairs, Taiwan

More information

Organs on Chips: The Future of Translational Research

Organs on Chips: The Future of Translational Research Organs on Chips: The Future of Translational Research KRISTIN FABRE, PHD SCIENTIFIC PROGRAM MANAGER NIH NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCE (NCATS) 1 Advancing regulatory sciences Drug

More information

Get to market. You want to develop medical devices that are safe, effective, and compliant. We ll show you the most efficient path.

Get to market. You want to develop medical devices that are safe, effective, and compliant. We ll show you the most efficient path. Get to market. You want to develop medical devices that are safe, effective, and compliant. We ll show you the most efficient path. Clinical Research Services We ve been the world s leading medical device

More information

International Transfers of Personal Data at sanofi-aventis R & D

International Transfers of Personal Data at sanofi-aventis R & D International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF

More information

Paradigm Shift in Comparability Assessment:

Paradigm Shift in Comparability Assessment: Paradigm Shift in Comparability Assessment: How Quality by Design (QbD) and Process Analytical Technology (PAT) can improve Structure-Activity Relationship (SAR) evaluation and its relevance to comparability

More information

GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE)

GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE) TriMark Publications April 2007 Volume: TMRGER07-0401 GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF CONTENTS

More information

Good Clinical Practice (GCP) & Clinical Trial Registries

Good Clinical Practice (GCP) & Clinical Trial Registries Good Clinical Practice (GCP) & Clinical Trial Registries The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practice Forum November 14-17, 2004 Kate Maloney, RN, MS, CPHQ Manager,

More information

INSTITUTE OF BIOMEDICAL SCIENCE

INSTITUTE OF BIOMEDICAL SCIENCE INSTITUTE OF BIOMEDICAL SCIENCE CORPORATE STRATEGY 2015-2018 Corporate Strategy 2015-2018 Page 1 of 8 Corporate Strategy 2015 2018 Vision, Mission and Values Our vision We aim to be the world s leading

More information